MedPath

Fluconazole

Generic Name
Fluconazole
Brand Names
Diflucan
Drug Type
Small Molecule
Chemical Formula
C13H12F2N6O
CAS Number
86386-73-4
Unique Ingredient Identifier
8VZV102JFY
Background

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.

Indication

Fluconazole can be administered in the treatment of the following fungal infections:

1) Vaginal yeast infections caused by Candida

2) Systemic Candida infections

3) Both esophageal and oropharyngeal candidiasis

4) Cryptococcal meningitis

5) UTI (urinary tract infection) by Candida

6) Peritonitis (inflammation of the peritoneum) caused by Candida

A note on fungal infection prophylaxis

Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.

A note on laboratory testing

Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.

Associated Conditions
Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis

Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.

Phase 3
Completed
Conditions
Invasive Candidiases
Interventions
Drug: Saline
First Posted Date
2023-05-08
Last Posted Date
2023-05-08
Lead Sponsor
Services Institute of Medical Sciences, Pakistan
Target Recruit Count
110
Registration Number
NCT05848492
Locations
🇵🇰

Services Hospital Lahore, Lahore, Punjab, Pakistan

Population Pharmacokinetics of Fluconazole in the Treatment of Neonatal Fungal Infectious Disease

Recruiting
Conditions
Infection
Pharmacokinetics
Fluconazole
Newborn
Interventions
First Posted Date
2023-03-20
Last Posted Date
2023-03-20
Lead Sponsor
Beijing Children's Hospital
Target Recruit Count
150
Registration Number
NCT05775692
Locations
🇨🇳

Beijing Children's Hospital of Capital Medical University, Beijing, Beijing, China

Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects

Phase 1
Completed
Conditions
Malignant Tumor
Interventions
Drug: SHR2554 Tablets
First Posted Date
2022-12-22
Last Posted Date
2023-04-04
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
18
Registration Number
NCT05661591
Locations
🇨🇳

Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

Phase 1
Completed
Conditions
Relapsed or Refractory Lymphoma
Interventions
First Posted Date
2022-11-02
Last Posted Date
2024-03-06
Lead Sponsor
Hutchmed
Target Recruit Count
59
Registration Number
NCT05602597
Locations
🇺🇸

QPS- Miami, Miami, Florida, United States

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

Phase 1
Completed
Conditions
Health Volunteers
Interventions
First Posted Date
2022-07-28
Last Posted Date
2022-08-30
Lead Sponsor
Concert Pharmaceuticals
Target Recruit Count
18
Registration Number
NCT05478772
Locations
🇺🇸

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

Not Applicable
Conditions
Cryptococcal Meningitis
Interventions
Drug: Amphotericin B Colloidal Dispersion
First Posted Date
2022-07-22
Last Posted Date
2022-07-22
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
30
Registration Number
NCT05471063
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Phase 3
Recruiting
Conditions
Candidemia
Candidiasis, Invasive
Interventions
First Posted Date
2022-06-16
Last Posted Date
2025-05-16
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
450
Registration Number
NCT05421858
Locations
🇮🇹

Hospital San Raffaele, IRCCS, Milan, Italy

🇮🇹

Polyclinic San Matteo, IRCCS, Pavia, Italy

🇮🇹

University Hospital of Pisa, Pisa, Italy

and more 67 locations

The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms

Phase 3
Recruiting
Conditions
Candidiasis, Vulvovaginal
Recurrent Candidiasis of Vagina
Interventions
Device: L-Mesitran
First Posted Date
2022-05-10
Last Posted Date
2023-05-17
Lead Sponsor
Maastricht University Medical Center
Target Recruit Count
252
Registration Number
NCT05367089
Locations
🇳🇱

Zuyderland Medical Centre, Heerlen, Netherlands

🇳🇱

MaastrichtUMC, Maastricht, Netherlands

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Phase 3
Suspended
Conditions
Candidiasis, Invasive
Candidemia
Interventions
First Posted Date
2022-01-05
Last Posted Date
2023-11-18
Lead Sponsor
Scynexis, Inc.
Target Recruit Count
220
Registration Number
NCT05178862
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

🇧🇪

Saint Luc University Hospital, Brussels, Belgium

and more 69 locations

Endothelial Derived Hyperpolarization Factor and Vascular Control

Phase 4
Recruiting
Conditions
Healthy
Interventions
First Posted Date
2022-01-04
Last Posted Date
2024-07-23
Lead Sponsor
University of Oklahoma
Target Recruit Count
30
Registration Number
NCT05176379
Locations
🇺🇸

Department of Health and Exercise Science, Norman, Oklahoma, United States

© Copyright 2025. All Rights Reserved by MedPath